AR degraders, T-cell engagers, and EZH2 inhibitors in #ProstateCancer pipeline. Maha Hussain, MD, FACP, FASCO @LurieCancer joins Oliver Sartor, MD @EJHospital surveying emerging prostate cancer therapies across disease states. Dr. Hussain notes that median survival in mCRPC has risen from approximately nine months in the late 1980s to more than three years currently. #WatchNow > bit.ly/4d6A14u

Cystoscopy vs urinary markers: A debate on #BladderCancer surveillance strategies. @UroDocAsh @UTMDAnderson moderates a debate between @jteoh_hk @CUHKMedicine & @LAUrology_NL @NKI_nl - does less invasive mean just as effective? Both agree that cystoscopy remains essential for high-risk disease, and favor risk-adapted, patient-preference-informed surveillance decisions. #WatchNow on UroToday > bit.ly/4chn3AC @IBCG_BladderCA

Analysis on the current state and future of #OveractiveBladder pharmacotherapy. Christopher Chapple, BSc, MD, FRCS (Urol), FEBU @SheffieldHosp joins Alan Wein, MD, PhD(hon), FACS @dsui_miami_uro to review pharmacologic targets in overactive bladder management. #WatchNow on UroToday > bit.ly/4lkAAvb #OAB

Rectal spacers in prostate radiotherapy: Balancing efficacy, safety, and patient experience. Michael Greenberg, MD @JeffersonUniv & @DanWelchons @AMPofNY join @zklaassen_md @GACancerCenter to discuss rectal spacing before #ProstateCancer radiotherapy. They trace the product evolution from SpaceOAR's pegylated hydrogel to Barrigel®. #WatchNow on UroToday > bit.ly/4cfWBs6 @Barrigel_spacer @teleflex

Evaluating EV plus pembrolizumab in muscle-invasive #BladderCancer: #KEYNOTEB15 results. @MattGalsky @TischCancer joins @ERPlimackMD @FoxChaseCancer to discuss this phase III trial randomizing 808 #MIBC patients to neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab versus gemcitabine-cisplatin. #WatchNow > bit.ly/4lGfZBP

Confronting the persistent gap between training and leadership for #WomenInHealthcare. Aparna Kamat, MD @MethodistHosp & @shilpaonc @ClevelandClinic join @UroDocAsh @UTMDAnderson to discuss Invoke Potential, addressing women's underrepresentation in medical leadership despite equal or greater medical school enrollment. #WatchNow > bit.ly/3PiK4eL

Women leading change in #BladderCancer: addressing diagnostic delays and unique needs. @JCensits @hopkinskimmel joins @TiansterZhang @UTSWMedCenter discussing @JohnsHopkins Women's Bladder Cancer Program co-led with urologic oncologist @akfsurgeon. #WatchNow on UroToday > bit.ly/4cTzX9U

⚡️ NEMIO trial published in @JCO_ASCO: neoadjuvant ddMVAC durvalumab in cisplatin-eligible MIBC (n=121). pCR 47.8%. Adding tremelimumab yields similar pCR but worse toxicity. Chemoimmunotherapy in the neoadjuvant setting: durvalumab adds value, tremelimumab does not. ascopubs.org/doi/10.1200/JCO… #BladderCancer #Immunotherapy

PTEN as a prognostic marker and clinical decision tool in #mHSPC: Multidisciplinary discussion. @Daniel_J_George, Neal Shore, MD, FACS, David Morris, MD, FACS & @neerajaiims review the CAPItello-281 Phase III trial, highlighting PTEN loss as a critical prognostic marker identifying a high-risk subset of patients with metastatic hormone-sensitive #ProstateCancer. #WatchNow > bit.ly/4slFxqL

How patient function and independence are changing advanced #ProstateCancer care. @KristineLacuna @MSKCancerCenter joins @zklaassen_md @GACancerCenter, emphasizing quality of life as a treatment success metric beyond overall survival in #mHSPC. #WatchNow on UroToday > bit.ly/3NuGlKw

Survey results on #ProstateCancer management treatment preferences in South Asia. @VedangMurthy @TataMemorial joins @neerajaiims @huntsmancancer describing the Indian approach to prostate cancer care. He outlines four practical principles guiding treatment decisions in resource-constrained settings. #WatchNow > bit.ly/4utRqv4

Radiopharmaceuticals in #ProstateCancer: Payloads, Carriers, Targets, and Combinations. Michael Morris, MD @MSKCancerCenter & @DrRanaMcKay @UCSanDiego join @DrPhilKantoff @ConvergentRx to discuss isotope and carrier selection, combination strategies, and emerging targets in radiopharmaceutical therapy. #WatchNow on UroToday > bit.ly/43eryrl

Evolving strategies in localized #ProstateCancer: From diagnosis to recurrence and future directions. Neal Shore, MD, FACS @TheSTARTCenter joins @PhillipKooMD @PCFnews to discuss localized prostate cancer unmet needs with advances in PSMA PET imaging correlating with MRI for treatment selection. #WatchNow > bit.ly/47ZuZ8b @CURCMB

Systematic review of vaginal lasers for stress urinary #incontinence. @Dr_i_pp_olito @UMichUrology joins Alan Wein, MD, PhD(hon), FACS @dsui_miami_uro reviewing nine RCTs of CO2 and Er:YAG vaginal lasers for stress urinary incontinence, showing no meaningful difference in continence rates versus sham and only a small, subclinical improvement in patient-reported incontinence scores. Evidence certainty was very low, no major adverse events were reported, and most studies used three laser sessions 30–45 days apart. #WatchNow > bit.ly/4b5Ac09

Radiopharmaceuticals in #ProstateCancer Part 2: Mechanisms and Clinical Considerations. @DrPhilKantoff @ConvergentRx, @ProfKHerrmann and @nhbander joins @PhillipKooMD to discuss alpha-emitting radiopharmaceuticals in prostate cancer. The discussion covers the properties of actinium-225, lead-212, and astatine-211; the trade-offs between small-molecule ligand and antibody-based delivery platforms; and combination strategies under investigation, including androgen pathway inhibitors with PSMA-targeted therapy, the CONV01 radioantibody with pembrolizumab, and antibody–ligand pairings. #WatchNow > bit.ly/4tyNyrR @PCFnews

Individual patient data analysis explores the benefit of adding immunotherapy to BCG in #BladderCancer. @UroDocAsh @UTMDAnderson joins @zklaassen_md @GACancerCenter to discuss a commentary analyzing BCG plus checkpoint inhibitor trials in #NMIBC. #WatchNow on UroToday > bit.ly/4sKNlC4 @JCO_ASCO

The #EMBRACETrial: An enhanced recovery after surgery pathway for transurethral resection of bladder tumors. @mihiggins22 & @MaxKates @brady_urology join @UroCancerMD to discuss an enhanced recovery protocol for ambulatory TURBT which improved Quality of Recovery-15 scores by 12 points—well above the 6-point clinical significance threshold—and reduced urethral pain, dysuria, incontinence, and 30-day outpatient visits. #WatchNow to learn more > bit.ly/3NqT3tH

Analysis of the phase III #CAPItello281 trial: Capivasertib Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard #mHSPC. #WatchNow > bit.ly/4q8vymh

More than a diagnosis: Global survey exposes the emotional and physical toll of #BladderCancer treatment. Gina Carithers @PCFnews joins @UroDocAsh @UTMDAnderson reflecting on the Bladder Burden Survey, which included responses from more than 800 patients and 800 urologists, and emphasized that many patients hesitate to share how bladder cancer affects daily life because they do not want to burden their doctors. She encourages clinicians to treat each visit as a personal conversation and highlights @BladderCancerUS and the @WorldBladderCan as key organizations expanding patient resources across languages and cultures. #WatchNow > bit.ly/4fvAZKz

CORE-008 Cohort CX: Early results of cretostimogene gemcitabine in BCG-unresponsive and BCG-exposed #NMIBC. @tbivala1 @PennCancer joins @UroCancerMD @VUMCurology to discuss data on cretostimogene plus intravesical gemcitabine in 55 BCG-unresponsive or BCG-exposed patients, showing high complete response rates of 95% at 3 months and 89.5% at 6 months. Efficacy was similar with sequential and concurrent dosing, though the concurrent arm had four discontinuations due to lower urinary tract symptoms. #WatchNow > bit.ly/4ulycrb